Novel ionically crosslinked casein nanoparticles for flutamide delivery: Formulation, characterization, and in vivo pharmacokinetics

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1721-1732

  Elzoghby, Ahmed O ^a   Helmy, Maged W ^b   Samy, Wael M ^a,c   Elgindy, Nazik A ^a  

^a Alexandria University Faculty of Pharmacy   (Egypt)

^b PHAROS UNIVERSITY IN ALEXANDRIA   (Egypt)

^c BEIRUT ARAB UNIVERSITY   (Lebanon)

Author keywords

Biodegradability; Casein nanoparticles; Controlled release; In vivo pharmacokinetics; Ionic crosslinking

Indexed keywords

CASEIN; DRUG CARRIER; FLUTAMIDE; NANOPARTICLE; TRIPOLYPHOSPHATE; TRYPSIN;

ANIMAL EXPERIMENT; ARTICLE; BIODEGRADABILITY; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; EMULSION; IN VIVO STUDY; ISOELECTRIC POINT; MALE; NONHUMAN; PARTICLE SIZE; PROTEIN CROSS LINKING; RAT; THERMAL ANALYSIS; ZETA POTENTIAL;

BIODEGRADABILITY; CASEIN NANOPARTICLES; CONTROLLED RELEASE; IN VIVO PHARMACOKINETICS; IONIC CROSSLINKING;

ANIMALS; CASEINS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; FLUTAMIDE; MALE; NANOPARTICLES; POLYPHOSPHATES; RATS; RATS, SPRAGUE-DAWLEY;

RATTUS;

EID: 84877093211     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S40674     Document Type: Article

References (39)

1. Chen L, Remondetto GE, Subirade M. Food protein-based materials as nutraceutical delivery systems. Trends Food Sci Technol. 2006;17: 272-283.
2. Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J. Control Release. 2012;161: 38-49.
3. Livney YD. Milk proteins as vehicles for bioactives. Curr Opin Colloid Interface Sci. 2010;15:73-83.
4. Elzoghby AO, Abo El-Fotoh WS, Elgindy NA. Casein-based formulations as promising controlled release drug delivery systems. J Control Release. 2011;153:206-216.
5. Semo E, Kesselman E, Danino D, Livney YD. Casein micelle as a natural nanocapsular vehicle for nutraceuticals. Food Hydrocoll. 2007;21: 936-942.
6. Zimet P, Rosenberg D, Livney YD. Re-assembled casein micelles and casein nanoparticles as nano-vehicles for ω-3 polyunsaturated fatty acids. Food Hydrocoll. 2011;25:1270-1276.
7. Esmaili M, Ghaffari SM, Moosavi-Movahedi Z, et al. Beta casein-micelle as a nano vehicle for solubility enhancement of curcumin; Food industry application. LWT Food Sci Technol. 2011;44:2166-2172.
8. Shapira A, Assaraf YG, Epstein D, Livney YD. β-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: Impact of drug structure and properties on co-assembly. Pharm Res. 2010;27: 2175-2186.
9. Shapira A, Davidson I, Avni N, Assaraf YG, Livney YD. β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: Stability, target-activated release and cytotoxicity. Eur J Pharm Biopharm. 2012;80:298-305.
10. Bachar M, Mandelbaum A, Portnaya I, Perlstein, et al. Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β-casein micelles. J Control Release. 2012;160: 164-171.
11. Elzoghby AO, Samy WM, Elgindy NA. Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release. 2012;167:168-182.
12. Elzoghby AO, Samy WM, Elgindy NA. Novel spray-dried genipin-crosslinked casein nanoparticles for prolonged release of alfuzosin hydrochloride. Pharm Res. 2013;30:512-522.
13. Martel CL, Gumerlock PH, Meyers FJ, Lara PN. Current strategies in the management of hormone refractory prostate cancer. Cancer Treat Rev. 2003;29:171-187.
14. Goldspiel BR, Kohler DR. Flutamide: an antiandrogen for advanced prostate cancer. DICP. 1990;24:616-623.
15. Zuo Z, kwon G, Stevenson B, Diakur J, Wiebe LI. Hydroxypropyl-β-cyclodextrin-flutamide inclusion complex. I. Formulation, physical characterization and absorption studies using the Caco-2 in vitro model. J Pharm Pharmaceut Sci. 2000;3:220-227.
16. Zuo Z, Tam YK, Diakur J, Wiebe LI. Hydroxypropyl-β-cyclodextrin flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in rat. J Pharm Pharmaceut Sci. 2002;5:292-298.
17. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug. flutamide. Eur J Pharm Biopharm. 2010;74:397-405.
18. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for preparation of amorphous flutamide dispersions. Drug Dev Ind Pharm. 2011;37:446-455.
19. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilized flutamide dispersions with polyols and amino acids: preparation and in vitro evaluation. Drug Dev Ind Pharm. 2011;37:446-455.
20. Elkhodairy K, Samy W. Optimization and evaluation of micromeritic and release properties of high dose flutamide liquisolid systems. Lett Drug Des Discov. 2012;9:336-344.
21. Murthy RSR, Umrethia ML. Optimization of formulation parameters for the preparation of flutamide liposomes by 3(3) factorial 26-term logit model. Pharm Dev Technol. 2004;9:369-377.
22. Madhusudhan B, Rambhau D, Apte SS, Gopinath D. Oral bioavailability of flutamide from 1-O-alkylglycerol stabilized o/w nanoemulsions. J Disp Sci Technol. 2007;28:1254-1261.
23. Jeevana JB, Sreelakshmi K. Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. J Young Pharm. 2011;3:4-8.
24. Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Biopolymeric microparticles combined with lyophilized monophase dispersions for controlled flutamide release. Int J Pharm. 2011;411:113-120.
25. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces. 2010;75: 1-18.
26. Ajun W, Yan S, Li G, Huili L. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr Polym. 2009;75:566-574.
27. Ye A, Flanagan J, Singh H. Formation of stable nanoparticles via electrostatic complexation between sodium caseinate and gum Arabic. Biopolym. 2006;82:121-133.
28. Anal AK, Tobiassen A, Flanagan J, Singh H. Preparation and characterization of nanoparticles formed by chitosan-caseinate interactions. Colloids Surf B Biointerfaces. 2008;64:104-110.
29. Rediguieri CF, de Freitas O, Lettinga MP, Tuinier R. Thermodynamic incompatibility and complex formation in pectin/caseinate mixtures. Biomacromolecules. 2007;8:3345-3354.
30. Gaiani C, Mullet M, Arab-Tehrany E, et al. Milk proteins differentiation and competitive adsorption during spray-drying. Food Hydrocoll. 2011;25:983-990.
31. Pan X, Yu S, Yao P, Shao Z. Self-assembly of β-casein and lysozyme. J Colloid Interf Sci. 2007;316:405-412.
32. Wu Y, Yang W, Wang C, Hu J, Shoukuan F. Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate. Int J Pharm. 2005;295:235-245.
33. Puthli S, Vavia P. Gamma irradiated micro system for long-term parenteral contraception: an alternative to synthetic polymers. Eur J Pharm Sci. 2008;35:307-317.
34. Gunasekaran S, Ko S, Xiao L. Use of whey proteins for encapsulation and controlled delivery applications. J Food Eng. 2007;83:31-40.
35. Jayakrishnan A, Knepp WA, Goldberg EP. Casein microspheres: preparation and evaluation as a carrier for controlled drug delivery. Int J Pharm. 1994;106:221-228.
36. Yoksana R, Jirawutthiwongchai J, Arpo K. Encapsulation of ascorbyl palmitate in chitosan nanoparticles by oil-in-water emulsion and ionic gelation processes. Colloids Surf B Biointerfaces. 2010;76:292-297.
37. Knepp WA, Jayakrishnan A, Quigg JM, Sitren HS, Bagnall JJ, Goldberg EP. Synthesis, properties, and intratumoral evaluation of mitoxantrone-loaded casein microspheres in Lewis lung carcinoma. J Pharm Pharmacol. 1993;45:887-891.
38. Latha MS, Lal AV, Kumary TV, Sreekumar R, Jayakrishnan A. Progesterone release from glutaraldehyde cross-linked casein microspheres: in vitro studies and in vivo response in rabbits. Contraception. 2000;61:329-334.
39. De Kruif CG, Zhulina EB. κ-Casein as a polyelectrolyte brush on the surface of casein micelles. Colloids Surf A. 1996;117:151-159.